Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 5:362:k3359.
doi: 10.1136/bmj.k3359.

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study

Rafel Ramos  1   2 , Marc Comas-Cufí  3   4 , Ruth Martí-Lluch  3   5 , Elisabeth Balló  3   2 , Anna Ponjoan  3   5 , Lia Alves-Cabratosa  3   4 , Jordi Blanch  3   4 , Jaume Marrugat  6   7 , Roberto Elosua  6   7 , María Grau  6   7 , Marc Elosua-Bayes  3   4 , Luis García-Ortiz  8 , Maria Garcia-Gil  3   4   2
Affiliations

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study

Rafel Ramos et al. BMJ. .

Abstract

Objective: To assess whether statin treatment is associated with a reduction in atherosclerotic cardiovascular disease (CVD) and mortality in old and very old adults with and without diabetes.

Design: Retrospective cohort study.

Setting: Database of the Catalan primary care system (SIDIAP), Spain, 2006-15.

Participants: 46 864 people aged 75 years or more without clinically recognised atherosclerotic CVD. Participants were stratified by presence of type 2 diabetes mellitus and as statin non-users or new users.

Main outcome measures: Incidences of atherosclerotic CVD and all cause mortality compared using Cox proportional hazards modelling, adjusted by the propensity score of statin treatment. The relation of age with the effect of statins was assessed using both a categorical approach, stratifying the analysis by old (75-84 years) and very old (≥85 years) age groups, and a continuous analysis, using an additive Cox proportional hazard model.

Results: The cohort included 46 864 participants (mean age 77 years; 63% women; median follow-up 5.6 years). In participants without diabetes, the hazard ratios for statin use in 75-84 year olds were 0.94 (95% confidence interval 0.86 to 1.04) for atherosclerotic CVD and 0.98 (0.91 to 1.05) for all cause mortality, and in those aged 85 and older were 0.93 (0.82 to 1.06) and 0.97 (0.90 to 1.05), respectively. In participants with diabetes, the hazard ratio of statin use in 75-84 year olds was 0.76 (0.65 to 0.89) for atherosclerotic CVD and 0.84 (0.75 to 0.94) for all cause mortality, and in those aged 85 and older were 0.82 (0.53 to 1.26) and 1.05 (0.86 to 1.28), respectively. Similarly, effect analysis of age in a continuous scale, using splines, corroborated the lack of beneficial statins effect for atherosclerotic CVD and all cause mortality in participants without diabetes older than 74 years. In participants with diabetes, statins showed a protective effect against atherosclerotic CVD and all cause mortality; this effect was substantially reduced beyond the age of 85 years and disappeared in nonagenarians.

Conclusions: In participants older than 74 years without type 2 diabetes, statin treatment was not associated with a reduction in atherosclerotic CVD or in all cause mortality, even when the incidence of atherosclerotic CVD was statistically significantly higher than the risk thresholds proposed for statin use. In the presence of diabetes, statin use was statistically significantly associated with reductions in the incidence of atherosclerotic CVD and in all cause mortality. This effect decreased after age 85 years and disappeared in nonagenarians.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
Flowchart of participant selection. SIDIAPQ=Information System for the Development of Research in Primary Care
Fig 2
Fig 2
Thin plate regression splines of hazard ratios of atherosclerotic cardiovascular disease and all cause mortality for statin use, by age, in participants with and without type 2 diabetes mellitus
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Statistics WH. Geneva. World Health Organization, 2015. [cited 2018 Jan 7], http://www.who.int/gho/publications/world_health_statistics/2015/.
    1. Marrugat J, Sala J, Manresa JM, et al. REGICOR Investigators Acute myocardial infarction population incidence and in-hospital management factors associated to 28-day case-fatality in the 65 year and older. Eur J Epidemiol 2004;19:231-7. 10.1023/B:EJEP.0000020446.57845.b0 - DOI - PubMed
    1. Ageing WP. 1950-2050. New York. United Nations, 2001. [cited 2018 Jan 10], http://www.un.org/esa/population/publications/worldageing19502050/.
    1. Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-8. 10.1161/01.CIR.96.12.4211 - DOI - PubMed
    1. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-9. 10.7326/0003-4819-129-9-199811010-00002 - DOI - PubMed

Publication types

MeSH terms

Substances